Yan Xin

594 total citations
11 papers, 455 citations indexed

About

Yan Xin is a scholar working on Genetics, Rheumatology and Hematology. According to data from OpenAlex, Yan Xin has authored 11 papers receiving a total of 455 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 4 papers in Rheumatology and 4 papers in Hematology. Recurrent topics in Yan Xin's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Respiratory viral infections research (2 papers). Yan Xin is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Respiratory viral infections research (2 papers). Yan Xin collaborates with scholars based in United States, Australia and Belgium. Yan Xin's co-authors include Robert Jordan, Richard J. Whitley, Stephen McBride, Thomas G. O’Riordan, Jason W. Chien, Xiaoming Li, Srini Ramanathan, Shao‐Lee Lin, Sandra A. Lewis and Rob Lambkin‐Williams and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and British Journal of Clinical Pharmacology.

In The Last Decade

Yan Xin

11 papers receiving 444 citations

Peers

Countries citing papers authored by Yan Xin

Since Specialization

Citations

This map shows the geographic impact of Yan Xin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yan Xin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yan Xin more than expected).

Fields of papers citing papers by Yan Xin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yan Xin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yan Xin. The network helps show where Yan Xin may publish in the future.

Co-authorship network of co-authors of Yan Xin

This figure shows the co-authorship network connecting the top 25 collaborators of Yan Xin. A scholar is included among the top collaborators of Yan Xin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yan Xin. Yan Xin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Pharmacokinetics of Fipaxalparant, a Small‐Molecule Selective Negative Allosteric Modulator of Lysophosphatidic Acid Receptor 1, and the Effect of Food in Healthy Volunteers 2024 ·Clinical Pharmacology in Drug Development ·(unknown), (unknown), (unknown), (unknown), (unknown), Yajing Sun, Yan Xin	5
2	SAT-432 Pharmacokinetics (PK) and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Blocking Antibody, in Active Thyroid Eye Disease (TED) 2020 ·Journal of the Endocrine Society ·Yan Xin, Fengyan Xu, Yuying Gao, (unknown), Jason Chamberlain, Maria Kovalenko, Saba Sile, Rui Sun, Robert A. Holt, Srini Ramanathan	2
3	Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects 2019 ·Clinical Pharmacology in Drug Development ·(unknown), Yan Xin, Hao Zheng, Chohee Yun, (unknown), Ann Qin, Florence Namour, Brian P. Kearney, Anita Mathias	7
4	Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor 2018 ·British Journal of Clinical Pharmacology ·Florence Namour, (unknown), Annegret Van der Aa, Pille Harrison, Yan Xin, Chantal Tasset	21
5	The Drug–Drug Interaction Profile of Presatovir 2018 ·The Journal of Clinical Pharmacology ·Yan Xin, (unknown), Bernard P. Murray, Eugene Eisenberg, Jason W. Chien, John Ling, Jeffrey A. Silverman	2
6	Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis 2017 ·Clinical Therapeutics ·David Gossage, (unknown), (unknown), Hao Zheng, Yan Xin, Preeti Lal, Guang Chen, Victoria Smith, John S. Sundy	43
7	A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia 2017 ·Leukemia Research ·Srđan Verstovšek, (unknown), Martin Grießhammer, Ruben A. Mesa, Carrie Baker Brachmann, Jun Kawashima, Julia D. Maltzman, Lixin Shao, Yan Xin, (unknown), Ashish Bajel	28
8	Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment 2017 ·The Journal of Clinical Pharmacology ·Yan Xin, Jun Kawashima, (unknown), (unknown), Thomas Tarnowski, Jeffrey A. Silverman	13
9	A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis 2016 ·Haematologica ·Vikas Gupta, Ruben A. Mesa, Michael W. Deininger, Candido E. Rivera, Shireen Sirhan, Carrie Baker Brachmann, Helen Collins, Jun Kawashima, Yan Xin, Srđan Verstovšek	77
10	Tu1945 Clinical Response to Anti-MMP9 Antibody (GS-5745) is Accompanied by Histologic Improvement in Ulcerative Colitis 2016 ·Gastroenterology ·William J. Sandborn, Bal Raj Bhandari, (unknown), Jane E. Onken, Elizabeth H. Yen, Erik G. Huntzicker, Yan Xin, Dorothy French, Jeffrey A. Silverman, Bittoo Kanwar, Mani Subramanian, John G. McHutchison, Scott Lee, Lisa M. Shackelton, Larry Stitt, Rish K. Pai, (unknown), Geert D’Haens, Brian G. Feagan	1
11	Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study 2014 ·New England Journal of Medicine ·John P. DeVincenzo, Richard J. Whitley, Richard L. Mackman, (unknown), Lisa Harrison, (unknown), Stephen McBride, Rob Lambkin‐Williams, Robert Jordan, Yan Xin, Srini Ramanathan, Thomas G. O’Riordan, Sandra A. Lewis, Xiaoming Li, Seth Toback, Shao‐Lee Lin, Jason W. Chien	256

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact